Patents by Inventor Zhi-yong Yang

Zhi-yong Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090214588
    Abstract: The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided.
    Type: Application
    Filed: July 15, 2005
    Publication date: August 27, 2009
    Inventors: Gary J. Nabel, Yue Huang, Zengguang Wang, Ling Xu, Bimal Chakrabarti, Lan Wu, Zhi-yong Yang, Jason G.D. Gall, C. Richter King
  • Publication number: 20090208531
    Abstract: These vaccines target H5N1, H1, H3 and other subtypes of influenza and are designed to elicit neutralizing antibodies, as well as cellular immunity. The DNA vaccines express hemagglutinin (HA) or nucleoprotein (NP) proteins from influenza which are codon optimized and/or contain modifications to protease cleavage sites of HA which affect the normal function of the protein. Adenoviral constructs expressing the same inserts have been engineered for prime boost strategies. Protein-based vaccines based on protein production from insect or mammalian cells using foldon trimerization stabilization domains with or without cleavage sites to assist in purification of such proteins have been developed. Another embodiment of this invention is the work with HA pseudotyped lentiviral vectors which would be used to screen for neutralizing antibodies in patients and to screen for diagnostic and therapeutic antivirals such as monoclonal antibodies.
    Type: Application
    Filed: February 16, 2007
    Publication date: August 20, 2009
    Applicant: National Institutes of Health Office of Technology
    Inventors: Gary J. Nabel, Wing-pui Kong, Zhi-yong Yang
  • Publication number: 20080286306
    Abstract: In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens.
    Type: Application
    Filed: June 13, 2007
    Publication date: November 20, 2008
    Inventors: Gary J. Nabel, Bimal Chakrabarti, Wing-pui Kong, Yue Huang, Zhi-yong Yang, Zengguang Wang
  • Publication number: 20080112997
    Abstract: The present invention describes DNA coated stents and methods of using the same to treat or prevent vascular diseases, such as restenosis.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 15, 2008
    Inventors: Elizabeth Nabel, Gary Natel, Zhi-Yong Yang
  • Publication number: 20080095835
    Abstract: The p21 gene encodes a cyclin dependent kinase inhibitor which affects cell cycle progression, but the role of this gene product in altering tumor growth has not been established. The present inventors have now discovered that the growth of malignant cells in vivo is inhibited by expression of p21. Expression of p21 resulted in an accumulation of cells in G0/G1, alteration in morphology, and cell differentiation.
    Type: Application
    Filed: October 31, 2007
    Publication date: April 24, 2008
    Inventors: Gary Nabel, Zhi-yong Yang, Elizabeth Nabel
  • Publication number: 20060275897
    Abstract: In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a singlr clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens.
    Type: Application
    Filed: March 15, 2006
    Publication date: December 7, 2006
    Inventors: Gary Nabel, Bimal Chakrabarti, Wing-pui Kong, Yue Huang, Zengguang Wang, Zhi-yong Yang
  • Publication number: 20060239975
    Abstract: The p21 gene encodes a cyclin dependent kinase inhibitor which affects cell cycle progression, but the role of this gene product in altering tumor growth has not been established. The present inventors have now discovered that the growth of malignant cells in vivo is inhibited by expression of p21. Expression of p21 resulted in an accumulation of cells in G0/G1, alteration in morphology, and cell differentiation.
    Type: Application
    Filed: June 27, 2006
    Publication date: October 26, 2006
    Inventors: Gary Nabel, Zhi-yong Yang, Elizabeth Nabel
  • Patent number: 7094598
    Abstract: The present invention relates generally to viral vaccines and, more particularly, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.
    Type: Grant
    Filed: November 24, 2004
    Date of Patent: August 22, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Gary J. Nabel, Zhi-yong Yang
  • Patent number: 7087582
    Abstract: The present invention provides a combination including a double-balloon catheter and a nucleic acid encoding the cyclin dependent kinase inhibitor p21. The nucleic acid may also encode HLA-B7, an immunotherapeutic agent, a cytokine or a prodrug converting enzyme.
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: August 8, 2006
    Assignee: Regents of the University of Michigan
    Inventors: Gary J. Nabel, Zhi-yong Yang, Elizabeth G. Nabel
  • Publication number: 20060148087
    Abstract: The present invention relates generally to viral vaccines and, more particularly, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.
    Type: Application
    Filed: November 24, 2004
    Publication date: July 6, 2006
    Inventors: Gary Nabel, Zhi-yong Yang
  • Publication number: 20050130129
    Abstract: The present invention provides compositions and methods for targeting gene transfer vectors to certain cell types by pseudotyping with a transmembrane form of viral glycoprotein, such as that from Ebola virus. The methods comprise the step of administering to a cell population a gene to be transferred operatively linked to an appropriate transfer vehicle, wherein the transfer vehicle is associated with a transmembrane form of viral glycoprotein.
    Type: Application
    Filed: June 3, 2004
    Publication date: June 16, 2005
    Inventors: Gary Nabel, Rafael Delgado, Zhi-yong Yang
  • Publication number: 20050038499
    Abstract: The present invention describes DNA coated stents and methods of using the same to treat or prevent vascular diseases, such as restenosis.
    Type: Application
    Filed: September 22, 2004
    Publication date: February 17, 2005
    Inventors: Elizabeth Nabel, Gary Nabel, Zhi-yong Yang
  • Publication number: 20040259825
    Abstract: The present invention relates generally to viral vaccines and, more particularly, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.
    Type: Application
    Filed: August 23, 2004
    Publication date: December 23, 2004
    Inventors: Gary Nabel, Zhi-yong Yang, Nancy Sullivan, Anthony Sanchez
  • Patent number: 6818016
    Abstract: The present invention describes DNA coated stents and methods of using the same to treat or prevent vascular diseases, such as restenosis.
    Type: Grant
    Filed: June 27, 1997
    Date of Patent: November 16, 2004
    Assignee: The Regents of the University of Michigan
    Inventors: Elizabeth G. Nabel, Gary J. Nabel, Zhi-yong Yang
  • Patent number: 6218372
    Abstract: The p21 gene encodes a cyclin dependent kinase inhibitor which affects cell cycle progression, but the role of this gene product in altering tumor growth has not been established. The present inventors have now discovered that the growth of malignant cells in vivo is inhibited by expression of p21. Expression of p21 resulted in an accumulation of cells in G0/G1, alteration in morphology, and cell differentiation.
    Type: Grant
    Filed: October 25, 1999
    Date of Patent: April 17, 2001
    Assignee: The Trustees of the University of Michigan
    Inventors: Gary J. Nabel, Zhi-yong Yang, Elizabeth G. Nabel
  • Patent number: 6057300
    Abstract: The p21 gene encodes a cyclin dependent kinase inhibitor which affects cell cycle progression, but the role of this gene product in altering tumor growth has not been established. The present inventors have now discovered that the growth of malignant cells in vivo is inhibited by expression of p21. Expression of p21 resulted in an accumulation of cells in G.sub.0 /G.sub.1, alteration in morphology, and cell differentiation.
    Type: Grant
    Filed: February 26, 1998
    Date of Patent: May 2, 2000
    Assignee: University of Michigan
    Inventors: Gary J. Nabel, Zhi-yong Yang, Elizabeth G. Nabel
  • Patent number: 5863904
    Abstract: The p21 gene encodes a cyclin dependent kinase inhibitor which affects cell cycle progression, but the role of this gene product in altering tumor growth has not been established. The present inventors have now discovered that the growth of malignant cells in vivo is inhibited by expression of p21. Expression of p21 resulted in an accumulation of cells in G.sub.0 /G.sub.1, alteration in morphology, and cell differentiation.
    Type: Grant
    Filed: September 26, 1995
    Date of Patent: January 26, 1999
    Assignee: The University of Michigan
    Inventors: Gary J. Nabel, Zhi-yong Yang, Elizabeth G. Nabel
  • Patent number: 5650306
    Abstract: This invention provides recombinant nucleic acid molecules for enhanced expression of genes that inhibit HIV gene expression. Cells transfected with these recombinant nucleic acids exhibit prolonged cell life. This invention also provides methods of treating individuals infected with HIV by introducing into them the transfected cells of this invention.
    Type: Grant
    Filed: June 7, 1993
    Date of Patent: July 22, 1997
    Assignee: University of Michigan
    Inventors: Gary J. Nabel, Zhi-Yong Yang, Jinsong Liu, Clive Woffendin